Skip to main content
. 2020 May 25;20:206. doi: 10.1186/s12886-020-01468-z

Fig. 2.

Fig. 2

Change in visual acuity over 12 and 24 months according to intravitreal aflibercept regimen. Observed analysis. *P < 0.05 versus baseline. BCVA best-corrected visual acuity, FAS full analysis set, IDs, initial doses, irreg irregular, reg regular, n number or patients